Su, Yunpeng <br/><br/>
Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials.  [electronic resource] 

 -  Biologicals : journal of the International Association of Biological Standardization  Jan 2010 
 - 144-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1095-8320 
<br/><br/><label>Standard No.: </label>10.1016/j.biologicals.2009.08.016  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amino Acid Substitution<br/>Bone Marrow Cells--drug effects<br/>Cells, Cultured<br/>Clinical Trials, Phase I as Topic--methods<br/>Diphtheria Toxin--adverse effects<br/>Drug Compounding--methods<br/>Drug Contamination--prevention & control<br/>Drug Evaluation, Preclinical<br/>Drug Stability<br/>Genetic Variation--physiology<br/>Humans<br/>Interleukin-3--adverse effects<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Lysine--genetics<br/>Recombinant Fusion Proteins--adverse effects<br/>Sterilization<br/>Toxicity Tests<br/>Tryptophan--genetics